Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Glioblastoma 2Brain Neoplasms 2

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × trans-sodium crocetinate × Clear all
NCT03393000 2021-07-22

INTACT

Diffusion Pharmaceuticals Inc

Phase 3 Terminated
19 enrolled 8 charts
CNS

Glioblastoma

NCT01465347 2017-07-14

Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

Diffusion Pharmaceuticals Inc

Phase 1/2 Completed
59 enrolled 10 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡